07:00 , Oct 29, 2007 |  BioCentury  |  Strategy

Amarin takes heart

Amarin Corp. plc has always known that its lead CNS compound, Miraxion , has potential applications in cardiovascular disease. However, the compound's failure in two Phase III trials for Huntington's disease last April led the...